Clinical trials: Tumor Infiltrating Lymphocytes
Sarcoma, Soft Tissue Sarcoma (STS)
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced soft tissue sarcoma ('SARATOGA')
- Conditions
- Sarcoma, Soft Tissue Sarcoma (STS), Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)
- Trial name
- 'SARATOGA' (NCT07741877)
- Testing
- Lifileucel
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Iovance Biotherapeutics, Inc.
HNSCC, Melanoma
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies.
- Conditions
- HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer
- Trial name
- ACT (NCT05902520)
- Testing
- DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- AgonOx, Inc.
Metastatic Melanoma
TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma
This is an open-label, phase 1, first-in-human (FIH), dose-escalation, multicenter, multinational trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy and in association with T-cell therapy with TILs in…
- Trial name
- TUNINTIL (NCT04217473)
- Testing
- TILT-123
- Where
- 2 sites in Denmark, France
- Volunteers
- 17 people
- Sponsor
- TILT Biotherapeutics Ltd.
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer
CISH Inactivated TILs in the Treatment of NSCLC
A clinical trial to assess the safety and efficacy of genetically-engineered Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- CheckCell-2 (NCT05566223)
- Testing
- Fludarabine, Cyclophosphamide, CISH Inactivated TIL
- Where
- 2 sites in United States
- Sponsor
- Intima Bioscience, Inc.
Advanced Solid Tumors
Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors
This is a multicenter Phase I/II clinical trial. It aims to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of GT201 in patients with advanced solid tumors.
- Trial name
- NCT06144671
- Testing
- GT201, IL-2, PD-1 inhibitor
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Grit Biotechnology
Adult
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
This is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants…
- Trial name
- NCT06241781
- Testing
- GT101 injection, Gemcitabine injection
- Where
- 24 sites in China
- Volunteers
- 83 people
- Sponsor
- Grit Biotechnology
Epithelial Ovarian Cancer, Non-small Cell Lung Cancer
ITIL-306 in Advanced Solid Tumors
ITIL-306-201 is a phase 1a/1b, multicenter, clinical trial evaluating the safety and feasibility of ITIL-306 in adult participants with advanced solid tumors whose disease has progressed after standard therapy.
- Conditions
- Epithelial Ovarian Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT05397093
- Testing
- ITIL-306
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Instil Bio
Ovarian Cancer Metastatic
OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)
An open label, multi-centre Phase 1/2a study of modified and unmodified autologous Tumour Infiltrating Lymphocytes (TIL) in patients with platinum-resistant ovarian cancer.
- Trial name
- OVSTAR (NCT04389229)
- Testing
- cyclophosphamide, fludarabine, IL-2 (Proleukin)
- Where
- 2 sites in United Kingdom
- Sponsor
- Immetacyte Ltd
Solid Tumor, Gynecological Tumors
Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors)
This study is a single-arm, open clinical trial.This trial consists of two phases, dose-escalation and expansion, and the study process is divided into: a screening period, a sampling and production period, a NMA-LD chemotherapy…
- Trial name
- NCT06145802
- Testing
- GT316
- Sponsor
- Grit Biotechnology
Advanced Solid Tumors
A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors
This study adopts a single-center, single-arm, open-label design. It aims to evaluate the safety and tolerability of GT307 in patients with advanced solid tumors, as well as assess its pharmacokinetic profile and efficacy, and…
- Trial name
- NCT07534813
- Testing
- GT307 injection
- Where
- China
- Sponsor
- Grit Biotechnology
Advanced Melanoma, Tumor Infiltrating Lymphocyte
A Study of GC101 TIL in Advanced Melanoma (10hospital)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma. Autologous TILs are expanded from tumor resections or biopsies and infused i.v.
- Conditions
- Advanced Melanoma, Tumor Infiltrating Lymphocyte, Treatment Side Effects, Effects of Immunotherapy
- Trial name
- NCT05098184
- Testing
- Tumor Infiltrating Lymphocyte
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Solid Tumor
Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors
This study is a multi-center, single-arm phase I clinical trial. A total of 26~42 subjects (20 evaluable cases are expected) from 1 cohort will be enrolled in this study.
- Trial name
- NCT05729399
- Testing
- GT201
- Where
- 3 sites in China
- Volunteers
- 6 people
- Sponsor
- Grit Biotechnology
Adult
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307) for treatment of patients with solid tumours,while evaluating pharmacokinetic…
- Trial name
- NCT06453057
- Testing
- GT307 injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Grit Biotechnology
Advanced Solid Tumor, Tumor Infiltrating Lymphocytes
A Study of TIL in Advanced Solid Tumors (DFGD)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
- Trial name
- NCT06488950
- Testing
- GC203 TIL(gene-edited TIL) or autologous TILs
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Juncell Therapeutics
Squamous Cell Carcinoma of the Head and Neck
Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
Multicenter, multicohort, non-randomized, prospective, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145/LN-145-S1) followed by IL-2…
- Trial name
- NCT03083873
- Testing
- LN-145, LN-145-S1
- Where
- 22 sites in United States
- Volunteers
- 64 people
- Sponsor
- Iovance Biotherapeutics, Inc.
HNSCC
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
This study is a single-arm early exploratory clinical study. designed to evaluate the safety and tolerability of GT201 in combination with a PD-1 inhibitor for the treatment of advanced head and neck tumor subjects with safety…
- Trial name
- NCT06190275
- Testing
- GT201 in combination with PD-1 inhibitors
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Grit Biotechnology
Endometrial Cancer
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
- Trial name
- NCT06481592
- Testing
- Lifileucel
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Iovance Biotherapeutics, Inc.